Expand NBIX Menu
NBIX MENU

NBIX Latest Press Releases

-- January 26, 2026 --

Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia PRNewswire 8:30 AM

-- January 21, 2026 --

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results PRNewswire 4:01 PM

-- January 15, 2026 --

Neurocrine Biosciences Presents Head-to-Head INGREZZA (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR PRNewswire 8:30 AM

-- January 5, 2026 --

Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference PRNewswire 4:01 PM

-- December 16, 2025 --

Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology PRNewswire 4:01 PM

-- December 9, 2025 --

Neurocrine Biosciences to Host R&D Day on December 16 PRNewswire 4:01 PM

-- November 20, 2025 --

Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA (valbenazine) Capsules PRNewswire 8:30 AM

-- November 11, 2025 --

Neurocrine Biosciences to Present at Upcoming Investor Conferences PRNewswire 4:01 PM

-- November 10, 2025 --

Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder PRNewswire 4:05 PM

-- October 28, 2025 --

Neurocrine Biosciences Reports Third Quarter 2025 Financial Results PRNewswire 4:01 PM

-- October 17, 2025 --

Neurocrine Biosciences Presents New KINECT 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA (valbenazine) 40 mg Capsules PRNewswire 8:30 AM

-- October 7, 2025 --

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results PRNewswire 4:01 PM

-- October 6, 2025 --

Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise PRNewswire 4:05 PM
Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA (valbenazine) Capsules for Huntington's Disease Chorea PRNewswire 8:30 AM

-- September 23, 2025 --

Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease Burden PRNewswire 8:30 AM

-- September 22, 2025 --

Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder PRNewswire 8:30 AM

-- September 16, 2025 --

Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025 PRNewswire 4:05 PM
Market Data Delayed 15 Minutes